NewAmsterdam Pharma Company N.V. Adjustments For Decrease Increase In Other Operating Receivables
NewAmsterdam Pharma Company N.V. (NAMS) reported Adjustments For Decrease Increase In Other Operating Receivables of EUR 3.69 million for the 6-month period ending 2023-06-30, per its 6-K filed 2023-08-07.
Financial Statements › Notes › Receivables
ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables · last filed 2024-10-28
| Period end | Adjustments For Decrease Increase In Other Operating Receivables 6 month | Adjustments For Decrease Increase In Other Operating Receivables 12 month |
|---|---|---|
| 2023-06-30 | 3.69M EUR 6-K · filed 2023-08-07 | |
| 2022-12-31 | -3.98M EUR 20-F/A · filed 2024-10-28 | |
| 2022-06-30 | -6.69M EUR 6-K · filed 2023-08-07 | |
| 2021-12-31 | -4.42M EUR 20-F/A · filed 2024-10-28 | |
| 2020-12-31 | -1.36M EUR 20-F/A · filed 2024-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |